PanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production
PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.
PanTera, an IBA and SCK CEN joint venture, aims to secure the large-scale production of actinium-225 (225Ac), which is one of the most promising alpha-emitting radioisotopes to fight cancer. The funds raised will be used primarily toward the construction of a state-of-the-art production facility in Belgium. This facility will not only enable large-scale production, it will also help fulfill PanTera’s ultimate goal to improve the accessibility of future, innovative cancer therapy based on 225Ac and theranostics.
Oaklins’ team in Belgium acted as the sole financial advisor in this transaction.
Contáctese con el equipo de la transacción
Nicholas Matthyssens
Oaklins KBC Securities
Transacciones relacionadas
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Aprenda másAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Aprenda másXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Aprenda más